In December of 2014, the Food and Drug Administration (FDA) approved olaparib (LYNPARZA, KuDOS/AstraZeneca), a first-in-class PARP inhibitor (PARPi), to treat patients with advanced ovarian cancers and also with BRCA1/2 mutations who have previously been treated with multiple rounds of chemotherapy (Kim et al., 2015). Here, PARP1 is linked to ovarian carcinoma.